New drug combo aims to stop deadly brain cancer relapse in older patients
NCT ID NCT04627753
First seen Apr 29, 2026 · Last updated May 04, 2026 · Updated 1 time
Summary
This study tests whether a combination of two drugs (lenalidomide and rituximab) can keep primary CNS lymphoma from coming back after initial treatment. It is for patients who cannot have a stem cell transplant, often due to age or health. The goal is to improve how long people live without the cancer returning.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY CNS LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Samsung Medical Center
RECRUITINGSeoul, 135710, South Korea
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.